Nothing Special   »   [go: up one dir, main page]

AU2001252390A1 - Nucleic acid immunization - Google Patents

Nucleic acid immunization

Info

Publication number
AU2001252390A1
AU2001252390A1 AU2001252390A AU5239001A AU2001252390A1 AU 2001252390 A1 AU2001252390 A1 AU 2001252390A1 AU 2001252390 A AU2001252390 A AU 2001252390A AU 5239001 A AU5239001 A AU 5239001A AU 2001252390 A1 AU2001252390 A1 AU 2001252390A1
Authority
AU
Australia
Prior art keywords
nucleic acid
acid immunization
immunization
nucleic
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001252390A
Inventor
Michael D. Macklin
Lendon G Payne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Vaccines Inc
Original Assignee
Powderject Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Powderject Vaccines Inc filed Critical Powderject Vaccines Inc
Publication of AU2001252390A1 publication Critical patent/AU2001252390A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001252390A 2000-05-01 2001-05-01 Nucleic acid immunization Abandoned AU2001252390A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US20096800P 2000-05-01 2000-05-01
US56195100A 2000-05-01 2000-05-01
US60200968 2000-05-01
US09561951 2000-05-01
US21058000P 2000-06-08 2000-06-08
US60210580 2000-06-08
PCT/GB2001/001924 WO2001083528A2 (en) 2000-05-01 2001-05-01 Nucleic acid immunization

Publications (1)

Publication Number Publication Date
AU2001252390A1 true AU2001252390A1 (en) 2001-11-12

Family

ID=27394229

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001252390A Abandoned AU2001252390A1 (en) 2000-05-01 2001-05-01 Nucleic acid immunization

Country Status (3)

Country Link
EP (1) EP1282640A2 (en)
AU (1) AU2001252390A1 (en)
WO (1) WO2001083528A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0201701D0 (en) * 2002-06-05 2002-06-05 Gotovax Ab Treatment of epithelial tumors and infections
EP1545593A1 (en) 2002-09-27 2005-06-29 PowderJect Research Limited Nucleic acid coated particles
CA2566355C (en) 2004-05-18 2014-04-15 Vical Incorporated Influenza virus vaccine composition and methods of use
WO2007126887A2 (en) * 2006-03-27 2007-11-08 The Government Of The United States Of America Immunogenic compositions comprising polynucleotides encoding matrix protein 2 and methods of use
AU2007306936B2 (en) 2006-10-12 2014-02-06 The University Of Queensland Compositions and methods for modulating immune responses
WO2012058715A1 (en) 2010-11-01 2012-05-10 University Of Technology, Sydney Immune-modulating agents and uses therefor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
FR2751226B1 (en) * 1996-07-19 1998-11-27 Rhone Merieux POLYNUCLEOTIDE VACCINE FORMULA AGAINST HORSE PATHOLOGIES
US5916879A (en) * 1996-11-12 1999-06-29 St. Jude Children's Research Hospital DNA transcription unit vaccines that protect against avian influenza viruses and methods of use thereof
DE69832706T2 (en) * 1997-08-05 2006-08-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. IMMUNO-PROTECTING INFLUENZAANTIGEN AND ITS USE FOR VACCINATION
WO2000002591A1 (en) * 1998-07-09 2000-01-20 Merck & Co., Inc. Polynucleotide vaccine formulations

Also Published As

Publication number Publication date
EP1282640A2 (en) 2003-02-12
WO2001083528A2 (en) 2001-11-08
WO2001083528A3 (en) 2002-04-25

Similar Documents

Publication Publication Date Title
AU2002245184A1 (en) Nucleic acid amplification
AU2002325538A1 (en) Nucleic acid amplification methods
AU2001295732A1 (en) Concatenated nucleic acid sequences
AU2002257076A1 (en) Nucleic acid shuffling
AUPQ968300A0 (en) Chemical methods
AU2001244687A1 (en) Micro-array
AU2001261476A1 (en) Nucleic acid sequences for novel gpcrs
AU2001246703A1 (en) Dna immunization vectors
AU2001242625A1 (en) Gene sequence
AU2001273461A1 (en) Methods for recombinatorial nucleic acid synthesis
AU2001264247A1 (en) GASC1 gene
AU1738201A (en) Adjuvants for nucleic acid vaccines
AU2001240103A1 (en) Reproduction-specific genes
AU2001252390A1 (en) Nucleic acid immunization
HUP0203848A3 (en) Nucleic acid vaccination
AU2002366435A1 (en) Nucleic acid amplification
AU2001288839A1 (en) Self-rearranging dna vectors
AU2003224265A1 (en) Nucleic acid immunization
AU2001285743A1 (en) Adipose-related gene
AU2002327959A1 (en) Adjuvants for nucleic acid vaccines
AU2001256161A1 (en) Nail
AU2001292922A1 (en) Nucleic acid detection
AU2002347346A1 (en) Dna vaccine
AUPR223500A0 (en) Nucleic acid sequence
AU2001279929A1 (en) Means for targeting nucleic acid repeat regions